| Product Name | MF | CAS | Details |
|---|
| Theralizumab | 906068-56-2 | Details |
| Clivatuzumab | 1622075-09-5 | Details |
| DSPE-NHS | C49H89N2O13P | 1383932-86-2 | Details |
| TV 3279 | C16H20N2O2 | 209394-29-6 | Details |
| HDAC-IN-57 | C21H19N3O4 | 2716217-79-5 | Details |
| PLH1215 | 1332084-64-6 | Details |
| PLH2058 | 2525206-41-9 | Details |
| Enfortumab | 1448664-46-7 | Details |
| MyD88-IN-1 | C23H24N6O7S | 2911609-80-6 | Details |
| lorvotuzumab | 339306-30-8 | Details |
| Bivatuzumab | 214559-60-1 | Details |
| TNF-α-IN-9 | C17H14O4 | 2054199-25-4 | Details |
| 17β-HSD10-IN-1 | C16H13ClN4O3S | 2316765-78-1 | Details |
| P-gb-IN-1 | C30H28N2O6 | 2632874-49-6 | Details |
| AP-C2 | C18H16N4S | 682793-07-3 | Details |
| Nurr1 agonist 2 | C18H14O3S | 742058-34-0 | Details |
| Cbl-b-IN-5 | C17H17N5OS | 2368835-59-8 | Details |
| BCPA | C22H22Cl2N2O2 | 547731-67-9 | Details |
| HA5 | C15H10O5 | 2378406-17-6 | Details |
| BCAT-IN-4 | C19H14N2O4S | 406190-85-0 | Details |
| FC-116 | C21H20FNO4 | 2417298-29-2 | Details |
| SARS-CoV-2-IN-39 | C14H8ClF4NO3 | 2882823-03-0 | Details |
| A2B receptor antagonist 2 hydrochloride | C12H15N5.ClH | 724-70-9 | Details |
| MMP-9-IN-6 | C25H19NO2 | 2241964-36-1 | Details |
| 1H-Indole, 3,3'-(2-thienylmethylene)bis[2-methyl- | C23H20N2S | 138801-72-6 | Details |
| VU534 | C21H22FN3O3S2 | 923509-20-0 | Details |
| KSK67 | C22H27N3O2 | 2566715-93-1 | Details |
| Anti-inflammatory agent 51 | C22H22N6O6S | 2911610-03-0 | Details |
| KM02894 | C7H9N3OS2 | 116850-74-9 | Details |
| Z16078526 | C18H17N3O4S | 852222-94-7 | Details |
| JHU 75528 | C23H21Cl2N5O2 | 947696-17-5 | Details |
| Antiviral agent 34 | C29H33N3O2S | 945152-88-5 | Details |
| CCG-13514 | C25H25BrN2O2 | 423741-32-6 | Details |
| LSD1-IN-27 | C24H25N3 | 2904571-94-2 | Details |
| Topoisomerase II inhibitor 14 | C15H11Cl2N5 | 305343-00-4 | Details |
| MoTPS1-IN-1 | C23H27F3N2O4 | 2991072-02-5 | Details |
| PI3Kδ-IN-16 | C22H26N6O2 | 2766437-35-6 | Details |
| RN-1665 | C20H24F5N3O3S2 | 1803003-65-7 | Details |
| DJ4 | C19H16N4OS | 1681020-24-5 | Details |
| AST 7062601 | C18H15N3O4S | 675197-89-4 | Details |
| LW3 | C17H12F3N3O | 2803367-68-0 | Details |
| (1R,5S,6r)-N-(2-methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide L(+)-Tartaric acid | C16H23N3O2.C4H6O6 | 2919211-45-1 | Details |
| Tubulin polymerization-IN-55 | C22H24N2O4 | 2942396-29-2 | Details |
| Tubulin polymerization-IN-43 | C17H13F4N3O | 2773345-90-5 | Details |
| PAC1R antagonist 1 | C17H17ClN6O2 | 2305204-24-2 | Details |
| ALK-IN-26 | C24H23NO3S | 2447607-85-2 | Details |
| MY-1076 | C29H33NO9 | 3008262-76-5 | Details |
| XPW1 | C36H39ClFN7O2 | 2700286-66-2 | Details |
| QST4 | C16H13ClN4O2S2 | 2991427-35-9 | Details |
| Ipamorelin 2 Pivalic acid | C38H49N9O5 | Details |
| MC4033 | C16H13N3O3 | 28532-21-0 | Details |
| Enpp-1-IN-16 | C23H32N4O4 | 2289739-47-3 | Details |
| IRG1-IN-1 | C18H15FO4 | 2407652-42-8 | Details |
| D4R agonist-1 | C19H22N4S | 2826198-44-9 | Details |
| CpCDPK1/TgCDPK1-IN-1 | C18H17N5 | 1092788-23-2 | Details |
| Phosphatase-IN-1 | C16H16Cl2FNO2 | 2889356-55-0 | Details |
| a-MSH, amide Acetate(581-05-5 free base) | C77H109N21O19S | Details |
| LFHP-1c | C55H64N6O4 | 2102347-47-5 | Details |
| Aprocitentan | C16H14Br2N6O4S | 1103522-45-7 | Details |
| AMPK activator 12 | C23H24BrNO2 | 431920-24-0 | Details |
| Nrf2 activator-3 | C23H18F3N3O2 | 2766570-23-2 | Details |
| Estrogen receptor antagonist 8 | 2889370-92-5 | Details |
| SARS-CoV-2-IN-38 | 2882823-27-8 | Details |
| Tubulin inhibitor 32 | C18H19N3O3 | 2923531-39-7 | Details |
| PLpro/RBD-IN-1 | C13H10N4O | 1282451-83-5 | Details |
| Ogremorphin | C21H17N3OS | 352563-21-4 | Details |
| TIM-3-IN-2 | C25H23N3O6 | 1113126-49-0 | Details |
| KSK94 | C25H26N4O | 2566716-07-0 | Details |
| KSK68 | C23H28N2O2 | 2566715-91-9 | Details |
| Antimalarial agent 30 | C18H11F3N2 | 1597425-64-3 | Details |
| A09-003 | C23H26N4O | 2911646-14-3 | Details |
| Zharp2-1 | C19H18N3O2PS | 2772600-18-5 | Details |
| h-NTPDase-IN-2 | C19H16N4S | 2939933-03-4 | Details |
| h-NTPDase-IN-3 | C16H10N4S | 2939933-10-3 | Details |
| Lingdolinurad | C17H12BrN3O2 | 2088176-96-7 | Details |
| Trontinemab | 2568868-35-7 | Details |
| NSC 122393 | C20 H8 Br4 O5 | 73654-97-4 | Details |
| EGFR/ErbB-2 inhibitor-1 | C23H15ClFN3OS2 | 1135150-79-6 | Details |
| DHX9-IN-2 | C18H16ClN3O3S2 | 2973395-71-8 | Details |
| AC-099 hydrochloride | C9H9Cl2F3N4 | 849335-07-5 | Details |
| TNF/IFNγ-IN-1 | C20H23N3O6 | 876013-29-5 | Details |
| AKE-72 | C30H29F3N6O | 2566525-18-4 | Details |
| EBOV-IN-1 | C34H43N3O5 | 1335113-30-8 | Details |
| IR820-PTX | C99H112N4O21S2.Na | 2250419-19-1 | Details |
| Anti-inflammatory agent 49 | C21H22N8O3S | 851471-44-8 | Details |
| TIE-2/VEGFR-2 kinase-IN-5 | C21H13F6N5O2 | 1014407-83-0 | Details |
| JG-2016 | C18H21ClN4O3 | 2887480-87-5 | Details |
| EGFR-IN-87 | C28H33N7O2 | 1835666-87-9 | Details |
| 1-N-Methyl-4-mercaptohistidine disulfide | 73491-33-5 | Details |
| Usenamine A | C18H17NO6 | 1428417-60-0 | Details |
| Aneratrigine hydrochloride | C19H20ClF2N5O2S2.ClH | 2097163-75-0 | Details |
| B-Raf IN 16 | C20H19N5O3S | 2304746-24-3 | Details |
| SARS-CoV-2 3CLpro-IN-16 | C17H14N2OS | 352659-40-6 | Details |
| S5A1 | C27H33N3O4.ClH | 2055882-51-2 | Details |
| IDH2R140Q-IN-2 | C21H18F6N6O | 2749568-16-7 | Details |
| ADS032 | C22H29NO4S | 2757333-37-0 | Details |
| (S)-OSMI 3 | C32H35N3O9S2 | 2411972-78-4 | Details |
| 3,3'-Selenobisalanine | 61216-56-6 | Details |
| (Z)-Tenilapine | C17H16N4S2 | 82650-82-6 | Details |
| Tenilapine | 82650-83-7 | Details |
| Product Total： Product Page： | ||||
| 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 | ||||